MX2011011512A - Proteinas de union de factor h quimericas (fhbp) y metodos de uso. - Google Patents

Proteinas de union de factor h quimericas (fhbp) y metodos de uso.

Info

Publication number
MX2011011512A
MX2011011512A MX2011011512A MX2011011512A MX2011011512A MX 2011011512 A MX2011011512 A MX 2011011512A MX 2011011512 A MX2011011512 A MX 2011011512A MX 2011011512 A MX2011011512 A MX 2011011512A MX 2011011512 A MX2011011512 A MX 2011011512A
Authority
MX
Mexico
Prior art keywords
methods
fhbp
binding proteins
chimeric factor
chimeric
Prior art date
Application number
MX2011011512A
Other languages
English (en)
Inventor
Dan M Granoff
Peter Beernink
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of MX2011011512A publication Critical patent/MX2011011512A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan fHbps quiméricas que pueden provocar anticuerpos que son bactericidas para diferentes cepas variantes de fHbp de N. meningitidis, y métodos de uso.
MX2011011512A 2009-04-30 2010-04-29 Proteinas de union de factor h quimericas (fhbp) y metodos de uso. MX2011011512A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17442409P 2009-04-30 2009-04-30
PCT/US2010/033048 WO2010127172A2 (en) 2009-04-30 2010-04-29 Chimeric factor h binding proteins (fhbp) and methods of use

Publications (1)

Publication Number Publication Date
MX2011011512A true MX2011011512A (es) 2012-02-13

Family

ID=43032788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011512A MX2011011512A (es) 2009-04-30 2010-04-29 Proteinas de union de factor h quimericas (fhbp) y metodos de uso.

Country Status (10)

Country Link
US (2) US9266942B2 (es)
EP (1) EP2424563A4 (es)
JP (2) JP5883380B2 (es)
CN (1) CN102711814A (es)
AU (1) AU2010242905B2 (es)
BR (1) BRPI1013902A2 (es)
CA (1) CA2759400A1 (es)
MX (1) MX2011011512A (es)
NZ (1) NZ595361A (es)
WO (1) WO2010127172A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2552942B1 (en) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
EP3831406B1 (en) 2010-08-23 2024-06-05 Wyeth LLC Stable formulations of neisseria meningitidis rlp2086 antigens
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
MX351993B (es) 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US9619444B2 (en) 2013-03-15 2017-04-11 International Business Machines Corporation System and method for web content presentation management
CA2918547A1 (en) 2013-08-02 2015-02-05 Peter T. Beernink Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
CA3212723A1 (en) 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
AU2016262823A1 (en) * 2015-05-18 2017-12-07 Universita' Degli Studi Di Trento Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
CN107823638B (zh) * 2017-11-05 2020-01-03 北京智飞绿竹生物制药有限公司 一种b群脑膜炎球菌重组嵌合蛋白疫苗及其制备方法
CN115976088B (zh) * 2022-07-21 2023-09-19 深圳蓝晶生物科技有限公司 低内毒素含量的罗氏真养菌及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
LT2599503T (lt) 1998-10-16 2017-06-26 Biogen Ma Inc. Interferono beta-1a polimero konjugatai ir jų panaudojimas
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
US20070148729A1 (en) * 2003-01-15 2007-06-28 Farley John E Methods for increasing neisseria protein expression and compositions thereof
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
PT2682126T (pt) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2008125985A2 (en) 2007-04-11 2008-10-23 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
CA2695467A1 (en) 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2326726A4 (en) 2008-08-27 2011-09-28 Childrens Hosp & Res Ct Oak FACTOR-BASED H-FACTOR ASSAYS TO DETERMINE BACTERICIDE SERIAL ACTIVITY AGAINST NEISSERIA MENINGITIDIS
WO2010028096A2 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
EP2552942B1 (en) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof

Also Published As

Publication number Publication date
NZ595361A (en) 2013-09-27
JP2016040289A (ja) 2016-03-24
JP2012525151A (ja) 2012-10-22
CA2759400A1 (en) 2010-11-04
US20160235833A1 (en) 2016-08-18
AU2010242905B2 (en) 2014-10-23
JP5883380B2 (ja) 2016-03-15
AU2010242905A1 (en) 2011-10-20
EP2424563A4 (en) 2013-10-30
BRPI1013902A2 (pt) 2019-09-24
US9266942B2 (en) 2016-02-23
EP2424563A2 (en) 2012-03-07
WO2010127172A2 (en) 2010-11-04
WO2010127172A3 (en) 2012-10-04
CN102711814A (zh) 2012-10-03
US20120121637A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
MX2011011512A (es) Proteinas de union de factor h quimericas (fhbp) y metodos de uso.
WO2009114485A3 (en) Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
MY162791A (en) Anti-il-23 antibodies
PH12014501108A1 (en) Anti-il-36r antibodies
WO2010028096A3 (en) Peptides presenting an epitope of an a domain of factor h binding protein
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
TN2010000213A1 (en) Wise binding antibodies and epitopes
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
MX2013009362A (es) Anticuerpo contra el csf-1r.
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
EP2282773A4 (en) METHOD AND COMPOSITIONS FOR THE PREPARATION OF ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED NUCLEAR FUCOSYLATION
MX357193B (es) Moleculas de union anti-alfa sinucleina.
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX342860B (es) Conjugados de anticuerpo-fármaco.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MY187990A (en) Anti-cd40 antibodies
MX340295B (es) Anticuerpos monoclonales anti-c-met.
MY171841A (en) Antibody formulation
PH12014502406B1 (en) Anti-il-23p19 antibodies
EP2588592A4 (en) USE OF PERFUSION DECELLULARIZED ORGANS FOR AGGREGATE RECELLULARIZATION
MY170720A (en) Antibody formulations
MX2013007371A (es) Peptidos de enlace her2 radiomarcados.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: CHILDREN S HOSPITAL & RESEARCH CENTER AT OAKLAND